BETHESDA, MD — September 11, 2025 — Leads & Copy — Lunai Bioworks Inc.’s (NASDAQ:RENB) subsidiary BioSymetrics Inc. has been awarded a Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) to develop an AI-driven platform for Alcohol Use Disorder (AUD) drug discovery.
The $1.85M USD grant, awarded jointly to BioSymetrics and Brigham and Women’s Hospital by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), will support the integration of BioSymetrics’ machine learning tools with experimental phenotyping capabilities to accelerate the identification of novel small molecules for future therapies.
Dr. Gabe Musso, Chief Scientific Officer at BioSymetrics, noted the urgent unmet need for therapeutic innovation in AUD and expressed excitement about collaborating with Dr. Calum MacRae and his team at Brigham and Women’s Hospital to translate phenotypic insights into actionable drug candidates.
David Weinstein, CEO of Lunai Bioworks, stated that this funding is a natural extension of Lunai’s approach, harnessing AI and in vivo biology to identify therapies faster and with greater precision.
Dr. Calum MacRae, Vice Chair for Scientific Innovation at Brigham and Women’s Hospital, is co-leading the program.
Media Contact:
David Weinstein
Chief Executive Officer
investors@renovaro.com
Source: Lunai Bioworks Inc.
